IMMUNIC INC IMUX 深 滬
等待開盤 10-09 09:30:00 美东时间
7.435
-0.195
-2.56%
華盛通- 最 高7.65
- 今 開7.65
- 成交量 24.82万股
- 最 低 7.25
- 昨 收 7.63
- 總市值 1.01亿
- 52周最高 17.43
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 5.062
- 委 比 61.29%
- 總股本 1364.45万
- 歷史最高 289.90
- 量 比 0.68
- 振 幅 5.24%
- 歷史最低 5.062
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clinical, biomarker and preclinical data for its lead investigational asset, nuclear receptor-related 1 (N...
10-07 20:07
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.
09-10 18:13
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
Immunic ( ($IMUX) ) just unveiled an announcement. On September 9, 2026, Immuni...
09-09 21:30
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, ...
09-01 18:30
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45
Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.
08-17 21:08
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same period last year.
08-11 18:36
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis a...
08-11 04:05
